Thymalin regulatory status
Current status of Thymalin in the United States: Unscheduled. In sport: WADA status unclear. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Thymalin?
Regulatory: UnscheduledWADA: WADA status unclearVerified: Verified Sep 30, 2026
- FDA and compounding
- Thymalin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. As an animal tissue extract of undefined composition it is not a candidate for 503A bulk compounding, and it is not eligible for 503B outsourcing. It is registered as a prescription drug in Russia and some neighboring countries. Products sold in the United States under this name for human use are unapproved drugs.
- WADA
- WADA status unclear
- Access path
- Not legally available in the United States: no approved product and no 503A bulks listing.
- Prescription drug in Russia and some neighboring countries.
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Full Thymalin page: evidence, dosing in the literature, and sources
How has the status of Thymalin changed over time?
No dated regulatory event has been recorded for Thymalin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Thymalin and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [3]WADA Prohibited ListWADA, 2026
- [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026